SCHEMBL2796293

SCHEMBL2796293

CC1N=NS(=O)(=O)c2cc(Cl)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
CYP1A2 P05177 2/20 0.40
ABCC8 Q09428 2/20 0.40
KCNJ11 Q14654 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
LMNA P02545 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
THRB P10828 1/20 0.40
TSHR P16473 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GRIA1 P42261 4/20 0.39
GRIA2 P42262 4/20 0.39
GRIA3 P42263 4/20 0.39
GRIA4 P48058 4/20 0.39
CA2 P00918 3/20 0.39
CA1 P00915 2/20 0.39
CA12 O43570 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2791341 0.80 ALDH1A1 (0.37) ALDH1A1CYP1A2ABCC8KCNJ11KDM4E
SCHEMBL2790682 0.78 CA2 (0.37) ALDH1A1ABCC8KCNJ11KDM4ELMNA
SCHEMBL2793795 0.75 PKM (0.34) ALDH1A1CA2CA1CA12CA4
SCHEMBL3579238 0.66 CA1 (0.35) CA2CA1
SCHEMBL3588752 0.63 ALDH1A1 (0.46) ALDH1A1CYP1A2ABCC8KCNJ11KDM4E
SCHEMBL2792778 0.62 ALDH1A1 (0.38) ALDH1A1CYP1A2ABCC8KCNJ11KDM4E
SCHEMBL8285709 0.60 ALDH1A1 (0.54) ALDH1A1CYP1A2ABCC8KCNJ11KDM4E
SCHEMBL13242322 0.59 HTR2C (0.53) ALDH1A1KDM4ELMNACYP3A4TSHR
SCHEMBL10908011 0.58 ALDH1A1 (0.49) ALDH1A1CYP1A2ABCC8KCNJ11KDM4E
SCHEMBL5621775 0.57 CA12 (0.32) CA2CA1CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190778-A1 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENTARSASAG (HU) 2010-07-29 US disclosed
US-20100168087-A1 BENZO[1,2,3]THIADIAZINE DERIVATES EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2010-07-01 US disclosed
EP-2061777-A1 BENZOÝ1,2,3¨THIADIAZINE DERIVATIVES Egis Gyogyszergyar Nyilvánosan Múködó Részvénytársaság (HU) 2009-05-27 EP disclosed
WO-2008020255-A1 BENZO[1,2,3]THIADIAZINE DERIVATIVES EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársagág (HU) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190778-A1 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE TDO2, DHODH, DHPS ALDH1A1 45/4885CYP1A2 9/4885ABCC8 3443/4885
US-20100168087-A1 BENZO[1,2,3]THIADIAZINE DERIVATES SULT2A1, TPH1, CYP1A1 ALDH1A1 39/4885CYP1A2 10/4885ABCC8 3318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.